GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMAO.PFD) » Definitions » Piotroski F-Score

XOMA (XOMAO.PFD) Piotroski F-Score : 1 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is XOMA Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

XOMA has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for XOMA's Piotroski F-Score or its related term are showing as below:

XOMAO.PFD' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 1

During the past 13 years, the highest Piotroski F-Score of XOMA was 6. The lowest was 1. And the median was 4.


XOMA Piotroski F-Score Historical Data

The historical data trend for XOMA's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Piotroski F-Score Chart

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 6.00 5.00 4.00 1.00

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.00 2.00 2.00 1.00

Competitive Comparison of XOMA's Piotroski F-Score

For the Biotechnology subindustry, XOMA's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where XOMA's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -9.813 + -5.4 + -5.509 + -20.109 = $-40.83 Mil.
Cash Flow from Operations was -4.924 + -7.208 + -2.099 + -3.927 = $-18.16 Mil.
Revenue was 0.437 + 1.658 + 0.83 + 1.833 = $4.76 Mil.
Gross Profit was 0.437 + 1.658 + 0.83 + 1.833 = $4.76 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(140.382 + 133.664 + 125.661 + 124.094 + 234.301) / 5 = $151.6204 Mil.
Total Assets at the begining of this year (Dec22) was $140.38 Mil.
Long-Term Debt & Capital Lease Obligation was $118.85 Mil.
Total Current Assets was $169.31 Mil.
Total Current Liabilities was $19.50 Mil.
Net Income was -2.28 + -4.67 + -4.178 + -5.976 = $-17.10 Mil.

Revenue was 3.107 + 0.983 + 0.451 + 1.486 = $6.03 Mil.
Gross Profit was 3.107 + 0.983 + 0.451 + 1.486 = $6.03 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(166.562 + 159.16 + 154.222 + 146.131 + 140.382) / 5 = $153.2914 Mil.
Total Assets at the begining of last year (Dec21) was $166.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $61.25 Mil.
Total Current Liabilities was $6.82 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

XOMA's current Net Income (TTM) was -40.83. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

XOMA's current Cash Flow from Operations (TTM) was -18.16. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-40.831/140.382
=-0.29085638

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-17.104/166.562
=-0.10268849

XOMA's return on assets of this year was -0.29085638. XOMA's return on assets of last year was -0.10268849. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

XOMA's current Net Income (TTM) was -40.83. XOMA's current Cash Flow from Operations (TTM) was -18.16. ==> -18.16 > -40.83 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=118.853/151.6204
=0.78388528

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/153.2914
=0

XOMA's gearing of this year was 0.78388528. XOMA's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=169.313/19.499
=8.68316324

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=61.253/6.818
=8.98401291

XOMA's current ratio of this year was 8.68316324. XOMA's current ratio of last year was 8.98401291. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

XOMA's number of shares in issue this year was 0. XOMA's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4.758/4.758
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6.027/6.027
=1

XOMA's gross margin of this year was 1. XOMA's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=4.758/140.382
=0.03389323

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=6.027/166.562
=0.03618472

XOMA's asset turnover of this year was 0.03389323. XOMA's asset turnover of last year was 0.03618472. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

XOMA has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

XOMA  (NAS:XOMAO.PFD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


XOMA Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of XOMA's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMAO.PFD) Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

XOMA (XOMAO.PFD) Headlines

From GuruFocus

XOMA to Present at the 42nd Annual Cowen Health Care Conference

By GuruFocusNews GuruFocusNews 03-01-2022

XOMA to Present at 43rd Annual Cowen Health Care Conference

By sperokesalga sperokesalga 02-28-2023

XOMA Declares Quarterly Preferred Stock Dividends

By sperokesalga sperokesalga 03-21-2023

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-26-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-06-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-16-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 06-20-2022